Bard PowerPort Lawsuits Update

Bart PowerPort lawsuits catheter

Hundreds of adverse events associated with Bard PowerPort catheters have been reported to the FDA, and lawsuits are being filed against the manufacturers of the device over manufacturing and design problems that can cause certain parts of the catheter port and catheter tube to be susceptible to fracturing and migration.

If you have been injured after being implanted with a Bard PowerPort device, contact Nash & Franciskato at (877) 284-6600

Bard PowerPort lawsuits have some elements of:

  • Bard’s negligent failure to provide adequate warnings
  • Bard’s negligent design of the PowerPort, and
  • Strict liability based on a manufacturing defect

The design defects of the device have been linked to several serious injuries and fracturing events whereby small fragments of the catheter break free and travel throughout the bloodstream resulting in vascular damage and other serious injuries including fatalities, infections, blood clots, and emergency surgical procedures.


Bard PowerPort MDL

In August 2023, a Bard PowerPort multidistrict litigation (MDL) was formed to help manage the increasing number of claims being filed.

August 8, 2023. The U.S. JPML issued a transfer order, ordering all Bard PowerPort fracture and migration claims to be centralized in the U.S. District for the District of Arizona before the Honorable Judge David G. Campbell.

As of February 5, 2024, there were a total of 99 Bard PowerPort lawsuits pending consolidation.

Transfer Order, MDL No. 3081, filed 8/8/23

IN RE: BARD IMPLANTED PORT CATHETER PRODUCTS LIABILITY LITIGATION

The Bard PowerPort lawsuit is against Becton Dickinson and Company, and its subsidiaries, C.R. Bard. Inc. and Bard Access Systems Inc. Bard Access Systems Inc., owned by Becton, Dickinson and Company, manufactures and sells the Bard PowerPort Device.

Update on MDL/Legal Proceedings

Trials are expected to begin in 2026.

February 2. 2024 – Discovery is ongoing, and the parties are due back in court in Phoenix on March 1, 2024. The judge has asked that the parties finalize a preservation order that would apply to port devices that are explanted because of injury.

January 2024: According to a case management order (PDF) issued on January 9, 2024, the U.S. JPML was scheduled to hear oral arguments on whether to include several Bard PowerPort reservoir failure lawsuits in the ongoing multidistrict litigation. Complaints filed state the device is made of a nondurable plastic material that can become weak and prone to fracturing.

December 2023: Judge Campbell issued a group of 6 Case Management Orders (CMO 6-12), which cover all of the rules and procedures for how the MDL will proceed over the next 18 months, outlining the details of how the cases will move through discovery, followed by a bellwether selection process.

November 2023 – After a status conference, Judge Campbell entered a Master Complaint and a Short-Form Complaint so that the Plaintiffs may file their case directly into the MDL.

Judge Campbell has determined that six Bard PowerPort lawsuits will ultimately be chosen for the first bellwether trials.


Bard PowerPort

The Bard PowerPort is one of several varieties of port/catheter systems that have been designed, manufactured, marketed, and sold by Bard Access Systems, Inc. (a wholly owned subsidiary of Becton, Dickinson, and Company (BD).

The Bard PowerPort is placed under the skin to provide repeated access to the vascular system to deliver medication, IV fluids, nutrition, or blood products. They are commonly used for chemotherapy in cancer patients.

The Bard PowerPort has inherent design and manufacturing flaws that make the device prone to fracturing and migrating out of position. Made from a type of polyurethane and silicone, the device contains barium sulfate to make it more visible during imaging tests. Barium sulfate has been shown to degrade polyurethane and silicone when in contact with human tissue, thus resulting in severe injuries, such as:

  • Catheter fractures
  • Catheter migration
  • Deep vein thrombosis (DVT)
  • Damage to veins and blood vessels
  • Catheter infection and necrosis
  • Blood clots
  • Arterial puncture
  • Heart attack or myocardial infarction
  • Hematoma or hemorrhage
  • Hemothorax
  • Pulmonary pseudoaneurysm
  • Pulmonary embolism
  • Tachycardia
  • Collapsed lung
  • Stroke
  • and other serious injuries

Bart PowerPort lawsuits design problems manufacturing problems catheter fracturing migrating Bard PowerPortDo You Have a Bard PowerPort Lawsuit?

  • Did you receive a Bard PowerPort or other implantable port catheter?
  • Did your port catheter fracture, crack, or migrate?
  • Did you suffer severe physical injuries as a direct result of the problems experienced with your PowerPort implant?

If you believe something is wrong with your implanted port device or feel pain around the port device’s location,  see your doctor immediately to receive any necessary care.

Our Bard PowerPort lawyers will advocate on your behalf and handle the legal process for you, such as:

  • Determining liability
  • Gathering evidence
  • Assessing damages
  • Building a strong case
  • Navigating the litigation process

START YOUR FREE, CONFIDENTIAL CASE EVALUATION WITH ONE OF OUR TEAM TODAY!

If you or your loved one received any of the Bard PowerPorts and suffered an injury due to catheter migration or fracture, including infections, organ damage, and life-threatening blood clots, you may have a case against Bard and Becton Dickinson. Contact the law offices of Nash & Franciskato at (877) 284-6600. One of our experienced staff will speak with you personally and will provide you with a free, no-obligation review of your case.

FIND OUT IF YOU HAVE A BARD POWERPORT CASE

RESOURCES FOR YOU

Would you like to receive news and blog updates regularly? Sign up to receive our email newsletter. Your email address will only be used to send you our newsletter and respond to inquiries.

SIGN UP FOR EMAIL NEWSLETTER

Contact Us Today for Help!

  • This field is for validation purposes and should be left unchanged.